Electra Therapeutics, Inc. (ETRA)

Electra Therapeutics, Inc. is a clinical-stage biotechnology company developing antibody therapies for immune-mediated diseases and cancer. Its research centers on signal-regulatory proteins, a family of receptors found on immune cells, which the company targets to selectively remove the cells that drive disease.

The lead product candidate, ELA026, is a monoclonal antibody that binds to signal-regulatory proteins on myeloid cells and T cells and depletes them. Electra is developing it initially for secondary hemophagocytic lymphohistiocytosis, a rare and life-threatening hyperinflammatory syndrome for which approved treatment options are limited, and is exploring further immunology and oncology indications.

Founded in 2018, Electra Therapeutics is headquartered in South San Francisco, California. The company completed its initial public offering and listed its common stock on the Nasdaq Stock Market under the ticker ETRA in 2026.